FLT3 and leukemia: Treatment was feasible even in the elderly and surprisingly effective in combination with Sorafenib (SOME), achieving 72% CR/Cri in R/R FLT3-ITDmut AML, 33% transplant rate, 43.6 weeks median overall survival and 22.4 weeks leukemia-free survival among responders [102].